Within regulatory terminology utilized by the United States Food and Drug Administration, CRL stands for Complete Response Letter. This is an official official communication document that the regulatory agency issues to a pharmaceutical sponsor when a new drug application or biologics license application cannot be approved in its current form, outlining the specific deficiencies, additional clinical data requirements, or manufacturing modifications needed before approval can be reconsidered.